Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...
5d
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback